Innate-Adaptive Immunoregulation in Liver Transplant Ischemia/Reperfusion Injury
Innate-Adaptive Immunoregulation in Liver Transplant Ischemia/Reperfusion Injury
批准号:
9359428
负责人:
Jerzy W Kupiec-Weglinski
金额:
$168.58万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-08-01 至 2022-07-31
关键词:
AcuteAddressAffectAllogenicAllograftingBiopsyBiostatistics CoreCD4 Positive T LymphocytesCEACAM1Cessation of lifeClinicClinicalComplexCytoprotectionDependenceDevelopmentEnvironmentEventFunctional disorderGoalsGoldHepaticHepatocellular DamageHepatocyteHumanImmuneImmunobiologyImmunogeneticsImmunologicsImmunologyImpairmentIncidenceInferiorInflammationInflammatoryInterferon Type IIKnowledgeLaboratoriesLifeLiverLiver diseasesLiver neoplasmsMemoryMicrosurgeryMolecularMonitorMusNatural ImmunityOrganOrgan DonorOrgan PreservationOrgan ProcurementsOrgan TransplantationOutcomePathologicPathologyPathway interactionsPatient CarePatientsPhenotypeProcessRegulationReperfusion InjuryResearch PersonnelRoleSavingsSentinelSeveritiesSignal TransductionSolidSpecificitySterilityStressSumT-Cell ActivationT-LymphocyteTLR4 geneTNFRSF5 geneTNFSF5 geneTherapeuticTherapeutic InterventionTissuesTranslational ResearchTransplant RecipientsTransplantationadaptive immune responseadaptive immunityclinically relevantexhaustionexperienceimmunoregulationimprovedinnovative technologiesliver allograftliver inflammationliver ischemialiver transplantationmacrophagemembermemory CD4 T lymphocytemouse modelnovelprogramsresponseskillsstandard of caresuccesssynergismtooltranscriptomics
中文摘要
点击翻译按钮获取中文摘要
英文摘要
OVERALL – SUMMARY/ABSTRACT
Orthotopic liver transplantation (OLT) is the gold standard of care in patients with end-stage liver disease and
those with tumors of hepatic origin. However, the organ shortage has prompted the use of extended criteria
livers, which are particularly susceptible to ischemia-reperfusion injury (IRI), an inflammation/tissue damage
response, which is inevitable during organ procurement and preservation. We propose the overarching
hypothesis that liver IRI results from impaired regulation between innate (e.g., macrophage-dependent) and
adaptive (T cell-driven) immune mechanisms. Complementary skills and expertise of the team well-versed in the
study of organ IRI, basic immunology, liver immunobiology, and organ transplantation, both experimental and
clinical, are melded in this PPG initiative to better appreciate molecular mechanisms that operate at the hepatic
innate - adaptive immune interface. Project I focuses on a newly discovered TIM-3 – CEACAM1 negative
checkpoint regulation of innate – adaptive immune interface in IR-stressed iso-OLT. Aim 1 will elucidate
mechanisms by which CEACAM1 – TIM-3 signaling on host circulating CD4+ T cells promotes T cell dysfunction
phenotype via exhaustion-like mechanism in IRI–OLT. Aim 2 will investigate mechanisms by which
hepatocellular-specific CEACAM1 expression may discriminate between sterile inflammation/liver hepatocellular
damage vs. cytoprotection in IR-stressed iso-OLT. Project II will define mechanisms by which allo-specific CD4
T cells during the host rejection response influence liver IRI in clinically-relevant allogeneic OLT settings. Studies
focus on a subset of pre-existing effector memory CD4 T cells (TEM), which respond to allograft challenge via
Ag-dependent vs. Ag non-dependent pathways, involving reactivation to secrete IFN-γ or to promote CD154 -
CD40 signaling. Aim 1 will analyze the Ag-dependence of CD4 TEM, while Aim 2 will ascertain the role of
costimulatory molecules in IR-stressed allo-OLT. Project III examines reciprocal regulation of innate/adaptive
immune responses and determines the contribution of alloimmune memory on the incidence and severity of
hepatic IRI in human OLT. Aim 1 will determine the role of DAMPs/PRR signaling in the activation of innate and
adaptive immunity in human liver grafts under IR-stress. Aim 2 will delineate the pathological signature of IRI in
human OLT via transcriptomic profiling of IRI biopsies and characterize the acute and long-term
pro-inflammatory profile of IRI. Aim 3 will determine the molecular basis for crosstalk between innate and
adaptive immune networks in human OLT that suffer from IR-damage (synergy: Project I and II). These 3
Projects will be supported by an Administrative Core (Core A); Liver Microsurgery Core (Core B; supports
Project I and II); and Computational/Biostatistics Core (Core C; supports all 3 Projects). Relevance: The
ultimate shared goal of these well-integrated and interdependent Projects and Cores is to unravel clinically
relevant mechanisms that regulate hepatic IRI in OLT recipients. These should identify molecules as targets for a
possible therapeutic intervention against IR-stress, and promote cytoprotection in liver transplant patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
THE RELAXIN RECEPTOR GR/RXFP1 SIGNALING IN LIVER TRANSPLANT ISCHEMIA-REPERFUSION INJURY AND THE INFLAMMATION RESOLUTION
-
批准号:10101174
-
项目类别:
-
资助金额:$39.0万
-
财政年份:2020
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
THE RELAXIN RECEPTOR GR/RXFP1 SIGNALING IN LIVER TRANSPLANT ISCHEMIA-REPERFUSION INJURY AND THE INFLAMMATION RESOLUTION
-
批准号:10685284
-
项目类别:
-
资助金额:$39.0万
-
财政年份:2020
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
THE RELAXIN RECEPTOR GR/RXFP1 SIGNALING IN LIVER TRANSPLANT ISCHEMIA-REPERFUSION INJURY AND THE INFLAMMATION RESOLUTION
-
批准号:10472636
-
项目类别:
-
资助金额:$39.0万
-
财政年份:2020
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
THE RELAXIN RECEPTOR GR/RXFP1 SIGNALING IN LIVER TRANSPLANT ISCHEMIA-REPERFUSION INJURY AND THE INFLAMMATION RESOLUTION
-
批准号:10268216
-
项目类别:
-
资助金额:$39.0万
-
财政年份:2020
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Innate-Adaptive Immune Interface in Liver Ischemia-Reperfusion Injury
-
批准号:9975698
-
项目类别:
-
资助金额:$38.23万
-
财政年份:2017
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Admin Core
-
批准号:10328210
-
项目类别:
-
资助金额:$14.19万
-
财政年份:2017
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
CEACAM1 Alternative Splicing in Liver Ischemia-Reperfusion Injury
-
批准号:10622462
-
项目类别:
-
资助金额:$54.09万
-
财政年份:2017
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Admin Core
-
批准号:9975689
-
项目类别:
-
资助金额:$12.17万
-
财政年份:2017
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Innate-Adaptive Immunoregulation in Liver Transplant Ischemia/Reperfusion Injury
-
批准号:9975685
-
项目类别:
-
资助金额:$167.45万
-
财政年份:2017
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Innate-Adaptive Immunoregulation in Liver Transplant Ischemia/Reperfusion Injury
-
批准号:9750602
-
项目类别:
-
资助金额:$168.08万
-
财政年份:2017
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Admin Core
-
批准号:10622453
-
项目类别:
-
资助金额:$14.19万
-
财政年份:2017
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Innate-Adaptive Immunoregulation in Liver Transplant Ischemia/Reperfusion Injury
-
批准号:10622451
-
项目类别:
-
资助金额:$194.91万
-
财政年份:2017
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
CEACAM1 Alternative Splicing in Liver Ischemia-Reperfusion Injury
-
批准号:10328213
-
项目类别:
-
资助金额:$53.42万
-
财政年份:2017
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Innate-Adaptive Immunoregulation in Liver Transplant Ischemia/Reperfusion Injury
-
批准号:10328209
-
项目类别:
-
资助金额:$194.13万
-
财政年份:2017
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
TIM-3 Negative Costimulation Signaling at the Innate-Adaptive Immune interface in Liver Transplant Ischemia-Reperfusion Injury
-
批准号:9198218
-
项目类别:
-
资助金额:$34.65万
-
财政年份:2016
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
TIM-3 Negative Costimulation Signaling at the Innate-Adaptive Immune interface in Liver Transplant Ischemia-Reperfusion Injury
-
批准号:9005628
-
项目类别:
-
资助金额:$34.65万
-
财政年份:2016
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Tim Costimulation in Liver Transplant Ischemia Injury
-
批准号:9029320
-
项目类别:
-
资助金额:$34.65万
-
财政年份:2015
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Tim Costimulation in Liver Transplant Ischemia Injury
-
批准号:8895119
-
项目类别:
-
资助金额:$34.65万
-
财政年份:2015
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
HO1 ANDTLR4 IN LIVER ISCHEMIA/REPERFUSION INJURY IN TRANSPLANT RECIPIENTS
-
批准号:7808751
-
项目类别:
-
资助金额:$61.6万
-
财政年份:2009
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
HEME OXYGENASE-1 IN HEPATIC ISCHEMIA/REPERFUSION INJURY
-
批准号:6847822
-
项目类别:
-
资助金额:$33.55万
-
财政年份:2003
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
海外基金